ENXTPA:IPNPharmaceuticals
How Investors Are Reacting To Ipsen (ENXTPA:IPN) Expanding IQIRVO Evidence In Primary Biliary Cholangitis
In May 2026, Ipsen reported new late-breaking Phase III and real-world data at the European Association for the Study of the Liver congress showing IQIRVO improved fatigue, pruritus and key biochemical markers in primary biliary cholangitis, with a tolerability profile consistent with earlier studies.
The results further underline IQIRVO’s role as a differentiated second-line option in PBC, backed by both controlled trials and real-world evidence across multiple countries.
We’ll now examine...